PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
Rhea-AI Summary
NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD 2026 in Copenhagen on March 19, 2026. The presentation reviews Phase 2b PARADIGM findings and biomarker analyses that informed the design of the planned global Phase 3 PARAGON trial.
PARADIGM data were recently published in JAMA Neurology, and NeuroSense says it is actively engaging regulators as PARAGON — a multinational, randomized, double-blind, placebo-controlled study — is advanced to further evaluate PrimeC's safety and efficacy.
Positive
- Phase 2b PARADIGM provided clinical and biomarker insights informing Phase 3 design
- PARADIGM results published in JAMA Neurology, increasing scientific validation
- Planned PARAGON Phase 3 is multinational, randomized, double-blind, placebo-controlled
Negative
- No marketing authorization yet; PrimeC advancement depends on successful Phase 3 outcomes
- Public release contains no quantitative efficacy or safety figures for investor assessment
Key Figures
Market Reality Check
Peers on Argus
Biotech peers showed mixed action: some, like TENX and ITRM, were up, while others traded down, with no clear alignment to NRSN’s modest 0.89% gain.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Phase 2b results published | Positive | +1.4% | JAMA Neurology publication of PARADIGM Phase 2b ALS outcomes and biomarker data. |
| Mar 09 | Survival data presentation | Positive | -3.0% | Long-term PARADIGM survival data with 65% reduced death risk and >14-month benefit. |
| Feb 18 | Extended survival update | Positive | -14.7% | Extended Phase 2b survival analysis showing 36.3 vs 21.4 month median survival. |
| Feb 09 | Australian patent grant | Positive | +8.5% | Grant of Australian patent for PrimeC composition extending protection to October 2042. |
| Jan 21 | U.S. Alzheimer’s patent | Positive | -5.2% | USPTO grants PrimeC combination patent for Alzheimer’s, protection through 2043. |
Recent clinically positive ALS updates often saw mixed or negative price reactions, while IP wins produced one of the stronger positive moves.
Over the last few months, NeuroSense has advanced PrimeC and its IP position. On Jan 21, it gained a U.S. patent for Alzheimer’s, followed by an Australian composition patent on Feb 9. Extended PARADIGM survival data on Feb 18 and long-term survival data on Mar 9 showed a 65% death-risk reduction and >14-month survival benefit. JAMA Neurology then published PARADIGM results on Mar 16. Today’s conference presentation fits into this sequence of reinforcing ALS data and trial progression.
Regulatory & Risk Context
An effective Form F-3 shelf dated Jan 29, 2026 allows NeuroSense to offer up to $150,000,000 in securities and supports an at-the-market program of up to $6,525,000. The filing notes substantial doubt about the company’s ability to continue as a going concern, underscoring reliance on future financings under this shelf and ATM.
Market Pulse Summary
This announcement reinforces NeuroSense’s trajectory of advancing PrimeC from the PARADIGM Phase 2b trial toward a global Phase 3 PARAGON study, with new clinical and biomarker analyses shared at a major neurology meeting. It follows recently published JAMA Neurology results and prior survival data. Investors may watch for Phase 3 initiation details, regulatory feedback, and how the $150,000,000 shelf and $6,525,000 ATM are utilized to finance late-stage development.
Key Terms
amyotrophic lateral sclerosis medical
biomarker medical
randomized, double-blind, placebo-controlled medical
tdp-43 medical
marketing authorization regulatory
AI-generated analysis. Not financial advice.
Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"
Dr. Lunetta's presentation, titled "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial," will take place during the symposium "Mechanisms and Therapeutics in the ALS-FTD Spectrum (SOD-1, TDP-43, C9ORF72 and TMEM106B)."
The presentation will review key clinical and biomarker findings from the Phase 2b PARADIGM trial, which evaluated PrimeC in people living with ALS. The data provide important insights into disease mechanisms and treatment effects that helped inform the design of the company's global Phase 3 PARAGON trial, currently being advanced to further evaluate PrimeC's safety and efficacy.
"ALS is one of the most complex neurodegenerative diseases, and advancing therapeutic development requires the integration of rigorous clinical research with deeper biological insight," said Dr. Christian Lunetta. "The clinical findings emerging from the PARADIGM trial, together with the expanding biomarker analyses, provide an important scientific foundation as we advance toward the PARAGON Phase 3 study. I look forward to sharing these results with the scientific community at AD/PD 2026 and to contributing, together with fellow investigators, to the next stage of clinical development as we work to advance meaningful therapeutic options for people living with ALS."
"We are deeply appreciative of Dr. Lunetta's role in presenting these findings and of his contribution as part of the clinical investigator community behind this work," said Dr. Shiran Zimri, NeuroSense VP of Research and Development and Canada Country Lead. "The timing of this presentation, The timing of this presentation, coming just days after the publication of the PARADIGM results in JAMA Neurology and at such a highly regarded scientific forum, is especially meaningful. It creates a unique moment where robust, peer-reviewed data can immediately be brought into scientific exchange and critical discussion. For us, this is not only about sharing results, but about engaging the field in a deeper understanding of the clinical and biomarker insights from PARADIGM as we advance with urgency toward our global Phase 3 PARAGON study."
The PARAGON Phase 3 trial is planned as a multinational, randomized, double-blind, placebo-controlled study designed to further evaluate PrimeC's potential to slow disease progression in people living with ALS.
NeuroSense continues active engagement with regulatory authorities to advance PrimeC toward potential marketing authorization.
About NeuroSense
NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/primec-new-data-to-be-presented-at-adpd-2026-conference-302717318.html
SOURCE NeuroSense
FAQ
What new PrimeC data will NeuroSense (NRSN) present at AD/PD 2026 on March 19, 2026?
How did the PARADIGM Phase 2b results influence NeuroSense's (NRSN) Phase 3 PARAGON trial design?
Has NeuroSense (NRSN) published the PARADIGM results and where can investors find them?
What is the planned design of the PARAGON Phase 3 trial for PrimeC (NRSN)?
Will AD/PD 2026 presentation change PrimeC regulatory timelines for NeuroSense (NRSN)?
Does the NeuroSense (NRSN) announcement disclose PrimeC efficacy or safety figures from PARADIGM?
